Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZymoGenetics has announced that it will receive a $5 million milestone payment from Bayer HealthCare, which was triggered by the submission of the marketing authorization application to the European Medicines Agency for approval to market Recothrom thrombin, topical (recombinant).
Subscribe to our email newsletter
Bayer has filed with the European Medicines Agency for authorization to market Recothrom as a topical aid to control surgical bleeding.
Recothrom received FDA approval in January 2008. Recothrom is being commercialized in a global collaboration between ZymoGenetics and Bayer which began in June 2007.
Bruce Carter, CEO of ZymoGenetics, said: “Bayer’s filing for approval in Europe demonstrates their commitment to Recothrom. Bayer has been a valued partner in selling Recothrom, the first and only plasma-free thrombin, in the US and in driving the ex-US program forward.”